Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short period in 135 currently underway clinical trials (to 21st April 2020). Typically, the doses were 2 to 5 times greater than the AAO recommendation (adjusted to weight) to avoid toxic retinopathy, the most undesirable ocular side effect. Maximum cumulative doses up to 12,000 mg for chloroquine and 18,000 mg for hydroxychloroquine were found. In prophylaxis clinical trials, 72,000 mg and 22,500 mg were the maximum cumulative doses for hydroxychloroquine and chloroquine respectively. Only 48% of the clinical trials considered retinal impairment as an exclusion criterion, and just one referred to an ophthalmic examination previous to study inclusion. How chloroquine and hydroxychloroquine treatment affect patients with a previous retinal condition is still poorly understood. A comprehensive ophthalmological examination 6 months after treatment is recommended in this subgroup. This review provides an overview of this topic and sheds light on the challenges visual caregivers may face regarding these repurposed drugs.
PerinelSLaunayMBotelho-NeversÉ, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis2020; 71(16): 2227–2229.
5.
Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi2020; 43(0): E019, http://www.ncbi.nlm.nih.gov/pubmed/32164085 (accessed 15 April 2020).
6.
GautretPLagierJ-CParolaP, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Travel Med Infect Dis2020; 8: 101663, https://linkinghub.elsevier.com/retrieve/pii/S1477893920301319 (accessed 15 April 2020).
7.
KakodkarPKakaN.A comprehensive literature review on the clinical presentation, and management of the pandemic Coronavirus Disease 2019 history of the outbreak. Cureus2020; 12(4): e7560.
8.
YusufIHSharmaSLuqmaniR, et al. Hydroxychloroquine retinopathy. Eye2017; 31(6): 828–245.
9.
AbdulazizNShahARMcCuneWJ.Hydroxy-chloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol2018; 30(3): 249–255.
10.
WiącekMBobrowska-SnarskaDLubińskiW, et al. What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review. Niger J Clin Pract2017; 20: 919–923.
11.
DevauxCARolainJ-MColsonP, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?Int J Antimicrob Agents2020; 55(5): 105938, https://linkinghub.elsevier.com/retrieve/pii/S0924857920300881 (accessed 15 April 2020).
12.
RainsfordKDParkeALClifford-RashotteM, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology2015; 23(5): 231–269.
13.
OnoderaHSasakiSOtakeS, et al. General considerations in ocular toxicity risk assessment from the toxicologists’ viewpoints. J Toxicol Sci2015; 40(3): 295–307.
14.
Al-BariAA.Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother2014; 70(6): 1608–1621.
European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: cluster of pneumonia cases caused by a novel coronavirus, Wuhan, China. European Centre for Disease Prevention and Control. 2020, p. 1–10, https://www.who.int/health-topics/coronavirus (accessed 3 May 2020).
17.
PlantoneDKoudriavtsevaT.Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig2018; 38(8): 653–671.
18.
DettorakiMMoschosMM.The role of multifocal electroretinography in the assessment of drug-induced retinopathy: a review of the literature. Ophthalmic Res2016; 56(4): 169–1677, https://www.karger.com/Article/FullText/446321
19.
GautretPLagierJ-CParolaP, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents2020; 56(1): 105949, http://www.ncbi.nlm.nih.gov/pubmed/32205204
FantiniJDi ScalaCChahinianH, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020; 55(5): 105960, https://linkinghub.elsevier.com/retrieve/pii/S0924857920301102 (accessed 15 April 2020).
ConigliaroPCesareoMChimentiMS, et al. Take a look at the eyes in systemic Lupus Erythematosus: a novel point of view. Autoimmun Rev2019; 18(3): 247–254.
28.
Costedoat-ChalumeauNDunoguéBLerouxG, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol2015; 49(3): 317–326, http://link.springer.com/10.1007/s12016-015-8469-8
MellesRBMarmorMF.The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol2014; 132(12): 1453–1460.
31.
JorgeAUngCYoungLH, et al. Hydroxychloroquine retinopathy—implications of research advances for rheumatology care. Nat Rev Rheumatol2018; 14(12): 693–703.
ChhablaniPPAmbiyaVNairAG, et al. Retinal findings on OCT in systemic conditions. Semin Ophthalmol2018; 33(4): 525–546.
34.
TsangACAhmadi PirshahidSVirgiliG, et al. Hydroxy-chloroquine and chloroquine retinopathy. Ophthalmology2015; 122(6): 1239–1251.e4.
35.
CouturierAGiocanti-AuréganADupasB, et al. Mise à jour des recommandations sur la toxicité rétinienne des antipaludéens de synthèse. J Fr Ophtalmol2017; 40(9): 793–800.
36.
SinghAKASinghAKAShaikhA, et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr Clin Res Rev2020; 14(3): 241–246.
37.
LuCCChenMYChangYL.Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc2020; 83(6): 534–536.
38.
ShahSDasSJainA, et al. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Int J Rheum Dis2020; 23(5): 613–619.
39.
GbinigieKFrieK.Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open2020; 4(2): bjgpopen20X101069, http://www.ncbi.nlm.nih.gov/pubmed/32265182 (2020, accessed 15 April 2020).
40.
LaiC-CShihT-PKoW-C, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents2020; 55(3): 105924, https://linkinghub.elsevier.com/retrieve/pii/S0924857920300674 (accessed 15 April 2020).
41.
LiXZhangCLiuL, et al. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB J2020; 34(5): 6008–6016,
WangMCaoRZhangL, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res2020; 30: 269–271.
44.
AlhazzaniWMøllerMHArabiYM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med2020; 46(5): 854–887, http://guidecanada.org/ (accessed 16 April 2020).
Rizzi Malattie InfettiveMFrancesco Castelli Malattie InfettiveBNicola Latronico Anestesia RianimazioneB, et al. Vademecum per la cura delle persone con malattia da COVI-19. SIMIT. 2020.
Van IersselSDaubyNBottieauE, et al. Interim clinical guidelines for patients suspected of/confirmed with COVID-19 infection in Belgium, www.notifieruneffetindesirable.be (2020, accessed 19 April 2020).
49.
VollaardAGielingELindenP van der, et al. Medicamenteuze behandelopties bij patiënten met COVID-19 (infecties met SARS-CoV-2). SWAB. https://swab.nl/nl/covid-19#to_6 (2020, accessed 16 April 2020).
FDA. Fact sheet for health care providers emergency use authorization (eua) of chloroquine phosphate supplied from the strategic national stockpile for treatment of covid-19 in certain hospitalized patients. 2020; 1–7, https://dailymed.nlm.nih.gov/dailymed/ (2020, accessed 30 April 2020).
Garcia-CremadesMSolansBPHughesE, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther2020; 108(2): 253–263. http://www.ncbi.nlm.nih.gov/pubmed/32285930 (accessed 15 April 2020).
58.
MarmorMF.COVID-19 and Chloroquine/Hydroxy-chloroquine: is there Ophthalmological Concern?Am J Ophthalmol2020; 216: 19–20.
59.
LeungLSBNealJWWakeleeHA, et al. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol2015; 160(4): 799–805.e1.
60.
MarmorMFKellnerULaiTYY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology2016; 123(6): 1386–1394.
61.
XieMChenQ.Insight into 2019 novel coronavirus—an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis2020; 94: 119–124.
62.
SinghalT.A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr2020; 87(4): 281–286.
63.
LaiCCLiuYHWangCY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect2020; 53(3): 404–412.
ZhaiPDingYWuX, et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents2020; 105955.
66.
YusufIHFootBGallowayJ, et al. The royal college of ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye2018; 32(7): 1168–1173.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
